• Avalo outlined an IL-1β inhibitor strategy for immune-mediated inflammatory diseases, led by abdakibart in moderate-to-severe hidradenitis suppurativa.
• Phase 2 LOTUS met its primary endpoint, with 42.5% HiSCR75 at week 16 versus 25.6% for placebo across dose arms.
• HiSCR50 reached 61.7% across dose arms versus 40.7% for placebo; abdakibart was described as well tolerated with no neutropenia signal.
• Phase 3 initiation targeted for 1H 2027; AVTX-010 expected to advance to IND in 1H 2027.
• May 2026 financing totaled $431.3 million; cash runway expected to fund operations into 2029, including anticipated Phase 3 topline data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.